hucMSC derived exosomes promote functional recovery in spinal cord injury mice via attenuating inflammation

• DOI: 10.1016/j.msec.2018.04.006
• Publication Date: 2018-04-10T06:22:31Z
• Authors: Guodong Sun; Guangqiang Li; Dehai Li; Wanjun Huang; Renwen Zhang; Hua Zhang; Yuanyuan Duan; Baocheng Wang
• Keywords: Inflammation; Lipopolysaccharides; 0301 basic medicine; Arginase; Tetraspanin 30; Macrophages; Cell Polarity; Nitric Oxide Synthase Type II; Mesenchymal Stem Cells; Recovery of Function; Exosomes; Umbilical Cord; 3. Good health; Mice, Inbred C57BL; Mice; 03 medical and health sciences; Phenotype; Animals; Cytokines; Humans; Female; Locomotion; Spinal Cord Injuries

The exploration of effective spinal cord injury (SCI) healing still remain a great challenge due to the high morbidity, complex pathology and unclear targets. Human umbilical cord mesenchymal stem cells (hucMSC) play an important role in tissue regeneration. However, transplanting stem cells has a potential risk of teratogenicity. Recent studies have suggested that exosomes secreted by stem cells may contribute to tissue injury repair. We hypothesized that the application of hucMSC derived exosomes may be a potential way for SCI treatment. Our studies showed the hucMSC derived exosomes with a mean particle size of 70 nm could effectively trigger the bone marrow derived macrophage (BMDM) polarization from M1 to a M2 phenotype. In vivo studies demonstrated that the hucMSC derived exosomes could improve the functional recovery after SCI through down-regulation of the inflammatory cytokines, such as TNF-α, MIP-1α, IL-6 and IFN-γ. Collectively, our findings indicated that hucMSC derived exosomes could facilitate spinal cord injury healing via attenuating the inflammation of the injury region. Our results provided a new perspective and therapeutic strategy for the use of hucMSC derived exosomes in soft tissue repair.